Omission Of Claim Feature More Significant To Claim Interpretation Than That Feature's Inclusion In Specification Embodiment
Client Alert | 1 min read | 07.02.07
The Federal Circuit, in Saunders Group, Inc. v. Comfortrac, Inc., (No. 2006-1576, June 27, 2007), reverses and remands a district court’s grant of summary judgment finding noninfringement, after determining that the district court improperly limited the scope of certain claims to include a feature that was not recited in the claims. In so doing, the panel concludes that the change in claim language between the parent application and the continuation-in-part application, and the resulting inclusion of the particular claim feature in certain claims and its omission from other claims, “is a sufficiently powerful indicator as to the proper construction of the asserted claims that outweighs the portion of the specification in which the invention is described narrowly.” The claim construction issue is made particularly difficult, says the panel, by the failure of the applicants to expressly state to the examiner the extent to which they intended their new claims to depart from the scope of the claims in the predecessor applications.
Contacts
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today